Introduction
Gene therapy has emerged as a promising, but evolving treatment for a number of inherited and acquired diseases, including ischaemic heart disease. Although there have been a few promising trials in this setting using direct intramyocardial injection, 1,2 the limiting factor is efficient gene delivery. One of the major technical limitations to direct intramyocardial injection is the small volume of myocardium accessible for transfection. 3, 4 This drawback can only be partially overcome by performing multiple injections. 5 Delivery of a vector via the coronary circulation is an attractive solution since all of the myocardial territory supplied by a coronary artery is accessible. The potential of intracoronary gene delivery has been demonstrated ex vivo. 6 However, the technique used has limited clinical applicability. Initial results with intracoronary gene transfer in vivo appeared promising, with efficient adenoviral-mediated gene transfer to 30% of myocytes in a vascular territory of the rabbit heart. 7 In contrast intracoronary delivery of recombinant adenovirus in normal porcine arteries was inefficient. 8 We previously demonstrated that interpretation of results when using the LacZ reporter is complicated by potential artefacts that may in part explain this discrepancy. Further understanding of the factors involved in gene transfer by intracoronary delivery of recombinant adenovirus has been gained through a series of experiments involving Langendorff perfusion. 10, 11 These studies show that the coronary flow rate, absolute amount of virus, time spent in the coronary circulation and composition of perfusate were major factors affecting intracoronary gene transfer 10 and increasing capillary permeability leads to improvements in gene transfer efficiency. 11 A related model of intracoronary gene delivery has confirmed feasibility provided transcapillary pressure is increased by simultaneous occlusion of the aorta and pulmonary artery in the rat, 12 and more recently, the rabbit. 13 It is upon this background that we attempted to resolve these discrepancies by intracoronary delivery of recombinant adenovirus, in combination with manipulations to increase capillary permeability and dwell time.
Results

Intracoronary infusion of recombinant adenovirus
Engagement and injection of the left coronary ostium had little effect on haemodynamic parameters measured (Table 1) . Intracoronary infusion of recombinant adenovirus alone was inefficient (Table 2, Figure 1 ). Increasing the absolute amount and concentration of infused adenovirus did not improve efficiency, despite a 100-fold increase in both parameters (Table 2 ). There was no visible effect on the myocardial architecture of treated hearts, specifically there was no inflammation. 
Effect of vehicle composition
In an attempt to increase the efficiency by means other than viral titre, we altered the vehicle from virus storage medium (10% glycerol, 0.001 m MgCl 2 , 0.01 m TRIS at pH 7.4) to a nominal calcium free Krebs-Henseleit buffer. This did not result in any lasting change in haemodynamic parameters compared with adenovirus delivered in virus storage medium. However, neither did it increase gene transfer as assessed by ␤-galactosidase expression at day 3 (mean number of positive cells = 0 ± 0, 1 x 10 10 p.f.u., n = 4; versus 0 ± 0, 1 x 10 10 p.f.u., n = 4; day 3).
Effect of adenosine pretreatment
Intracoronary delivery of 1 mg of adenosine, 3 to 15 min before delivery of 1 x 10 11 p.f.u. of recombinant adenovirus did not effect any of the haemodynamic parameters measured. There was, however, an increase in PR interval duration of 30 ± 10% (0.051 ± 0.001 versus 0.065 ± 0.004 s, P Ͻ 0.005) immediately following adenosine infusion. Despite this evidence of adenosine receptor activation there was no increase in gene transfer compared with the adenovirus alone (mean number of positive cells = 10.3 ± 10 n = 11 versus 0.75 ± 0.75, n = 4; both at 1 x 10 11 p.f.u. at day 3, P = NS). In all sections there was no alteration in the microscopic appearance of the myocardium.
Effect of VEGF pre-treatment
Preliminary experiments were carried out to determine whether there was an increase in coronary vascular permeability following intracoronary infusion of human recombinant VEGF. When human recombinant VEGF was delivered 3 min before a 20-min Evans Blue infusion there was a three-fold increase in coronary vascular permeability (Evans Blue accumulation at: 3 min = 3.62 ± 0.2 * , n = 3; 10 min 1.26 ± 0.05, n = 3; saline at 3 min = 1.2 ± 0.1, n = 2; * P Ͻ 0.0001 versus both groups). Delivery of human recombinant VEGF 3 min before infusion of 1 x 10 11 p.f.u. of recombinant adenovirus had no significant effect on measured haemodynamic parameters compared with delivery of recombinant adenovirus alone. Despite the increase in vascular permeability, there was no increase in gene transfer as assessed by ␤-galactosidase staining (mean number of positive cells = 0 ± 0, n = 5 versus 0.75 ± 0.75, n = 4; both at 1 x 10 11 p.f.u. at day 3, P = NS).
Effect of occlusive catheter engagement
The use of oxygenated perfluorocarbon (PFC) as a vehicle for recombinant adenovirus delivery had no effect on baseline haemodynamic parameters ( Table 1 ). The use of PFCs allowed a more adventurous approach to cardiac catheterisation, enabling occlusive coronary engagements during infusion. This would have the theoretical advantage of arresting antegrade coronary flow and therefore admixture of virus and blood. There was a mean duration of ST elevation or ECG abnormality of 28 ± 15 s in the PFC-alone group. Consequently, this also allowed a similar approach to be taken when delivering recombinant adenovirus, with a mean duration of ST elevation or ECG abnormality (usually T wave inversion) of 24 ± Gene Therapy 16 s (n = 4). When delivering recombinant adenovirus in standard vehicle, the engagements were purposefully non-occlusive. Despite documented ST elevation, there was no effect on gene delivery efficiency (mean number of positive cells = 0 ± 0, PFC alone, n = 3 versus 0.25 ± 0.25, n = 4 both at 1 x 10 11 p.f.u. at day 3, P = NS).
Effect of high-pressure adenoviral delivery
High-pressure gene delivery by simultaneous occlusion of the aorta and pulmonary artery caused dramatic increases in the systolic and diastolic pressure in the left ventricle ( Figure 2 ). All hearts showed gross dilation at the time of the procedure, and flushing of the virus solution in the coronary arteries was always visualised.
There was a dramatic increase in gene delivery as assessed by ␤-galactosidase expression compared with normal pressure (mean number of positive cells per section 212 ± 118, n = 4, P Ͻ 0.01 versus normal pressure). Changing the vehicle had no significant effect on gene transfer (mean number of positive cells per section 129 ± 61, n = 4, P = NS versus high-pressure delivery). This procedure has been described in the literature as intracoronary delivery, 12 however we noted that there are numerous positive myocytes at the point of needle insertion. With both the normal buffer and the nominal calcium-free buffer, approximately a third of the transgene positive cells were in the vicinity of the needle track (35% and 31%, respectively).
Mortality of each technique
In total, four rabbits died during the study. In the high pressure infusion group, two rabbits failed to recovery their systemic pressures on release of the aortic and pulmonary artery cross-clamp, one rabbit died of electromechanical dissociation after nominal calcium-free perfusion and one rabbit died during virus infusion following VEGF pre-treatment. All deaths occurred during anaesthesia and data were not included in any of the analyses.
Discussion
These studies demonstrate that intracoronary delivery of recombinant adenovirus is an inefficient means of transfecting cardiac myocytes in vivo. In addition, manipulations that have previously been demonstrated to increase transfection efficiency in vitro do not improve gene transfer in vivo under physiological conditions. In contrast supraphysiological pressures at the time of recombinant adenoviral delivery do result in a dramatic improvement of efficiency.
Our results are in direct contrast to those of two previous studies performed in the rabbit 7 and mini-pig 14 despite use of almost identical recombinant adenoviruses. The Barr study 7 examined gene transfer, as detected histologically by cytoplasmic ␤-galactosidase, at days 5, 14, 28 and 56 after gene delivery. In this study 7 transfection efficiency at day 5, using 1 x 10 10 p.f.u., was greater than 30%. Even when we delivered 1 x 10 12 p.f.u. of recombinant adenovirus we did not detect transgene expression. The study by Giordano et al, 14 also found ␤-galactosidase reporter gene expression at days 3 and 5. However, the efficiency was lower than that reported by Barr et al. 7 Moreover, the circumstances of gene delivery differed markedly from those that we employed. The Giordano study 14 employed a model involving collateraldependent myocardium in the swine where perfusion reserve was severely compromised by an ameroid constrictor. Consequently myocardial ischaemia was easily induced, and likely to have been repetitive. Circumstances that are known to increase endothelial permeability, 15 possibly explaining the relatively high transfection efficiency. The relevance of the study by Giordano et al 14 to patients with ischaemic heart disease was immediately obvious. Thus, this study more than any other, has laid the foundation for current clinical trials of intracoronary infusion of adenoviral vectors to enhance collateral flow. However, in normal porcine myocardium, other investigators report transfection efficiencies consistent with our results. 8 Whilst it is hard to reconcile our data with those of some previous studies, the factors that have to be overcome for intracoronary delivery of recombinant adenovirus to result in expression of a transgene are numerous.
The first hurdle is ensuring escape of the adenovirus from the coronary circulation to the interstitium of the myocardium. The adenoviral virion is approximately 75 nm in diameter. 16 This is too large to pass through normal capillary endothelium. 11 This may explain why adeno-associated virus, with a smaller diameter, results in gene transfer by intracoronary infusion. 17 However, in our experience adenovirus has a greater comparative efficiency of transfection when delivered to the cardiac interstitium by intramyocardial injection. 4 Future studies are needed to determine whether the smaller diameter of adeno-associated virus, amongst other properties, would sufficiently improve delivery to the interstitium following intracoronary injection so as to overcome the inherently greater efficiency of adenovirus.
Using a Langendorff preparation, Donahue et al 10 demonstrated that increasing the coronary flow resulted in an increase in transfection efficiency. They suggested that the improvement of gene transfer was due to opening of precapillary sphincters, allowing free movement of the recombinant adenovirus into the interstitium. When virus was suspended in blood, the transfection efficiency decreased by approximately 30%. The other factor that they examined was the length of time the virus was in the coronary circulation. When 5 x 10 9 p.f.u. of recombinant virus was recirculated around the heart for 100 s less than 1% of cardiac myocytes were transfected. When the duration of virus recirculation was increased to 20 min, the transfection efficiency increased to 40%. 10 These results are also in keeping with a more recent study by Logeart et al. 18 Thus, it is likely that gene delivery in vivo would be less efficient due to the presence of blood, and that only one pass through the coronary circulation is unlikely to allow significant transfection.
In an attempt to improve access to the myocardium, we infused recombinant VEGF into the coronary circulation. This resulted in an increase in capillary permeability, as expected from previous work. [19] [20] [21] [22] [23] However, this did not increase gene transfer, nor did prior infusion of adenosine, a vasodilator, or changing the buffer to a nominal calcium-free Krebs-Henseleit solution, which has been demonstrated to increase gene delivery in vitro. 11 Similarly, the use of oxygenated perfluorocarbons, a blood substitute, to increase both the time the virus was in the coronary circulation and to exclude blood, did not improve gene delivery. It is likely that the lack of improvement of gene transfer seen with these manipulations is that, compared with the in vitro setting, the virus is still only in the coronary circulation for a relatively short period. Despite these drawbacks it is possible that efficiency would have been increased by superselective engagement of distal coronary artery branches. Though this recently described technique results in high efficiency in vivo delivery 24 it would not be applicable to a large area of diffusely diseased/ischaemic myocardium.
The final parameter that we investigated was the pressure within the coronary arteries at the time of gene delivery. Using a similar model to Hajjar et al, 12 who performed experiments in the rat, we have demonstrated that intraventricular injection of recombinant adenovirus results in relatively efficient gene transfer. Although, in contrast to other interventions, this technique required an open chest, there were no associated alterations in baseline haemodynamics to suggest an artifactual increase in transfection efficiency. Unlike the earlier experiments we noted that instead of being 'grossly homogenous', transgene expression was distributed in two distinct patterns. Whilst the majority of the transgene-positive cells were distributed throughout the ventricle, a third of the transgene-positive myocytes were distributed along the path of needle insertion. The results of all three studies 12, 13 employing high pressure are consistent, suggesting that this is a truly reproducible method of gene delivery. The resulting grossly unphysiological pressure in the coronary artery that we have demonstrated presumably increases the fenestrations between the capillary endothelial cells, allowing transit of the adenovirus to the cardiac myocytes.
Intracoronary gene delivery with recombinant adenovirus, although conceptually elegant, is inefficient in this model using physiologically relevant perfusion pressures. Further refinements in similarly relevant animal models are needed to optimise cardiac gene delivery for conditions requiring widespread transgene expression of non-secreted proteins.
Materials and methods
Animals
Sixty-four male New Zealand White rabbits (2.5-3.0 kg) at 10-12 weeks of age, maintained on a normal diet, were anaesthetised by intramuscular injection of 0.19 mg/kg fentanyl citrate and 6 mg/kg of fluanisone (Hypnorm; Janssen-Cilag, Bucks, UK) and 3 mg/kg diazepam (Diazemuls; Dumex, Hertfordshire, UK). All procedures were in accordance with the UK Home Office Animals (Scientific Protection) Act 1986.
Preparation of adenovirus vector A recombinant first generation (E1
Ϫ
/E3
Ϫ ) adenoviral vector encoding the E. coli nlsLacZ gene with SV40 polyA tail driven by the hCMV IE promoter/enhancer was made by homologous recombination in HEK 293 cells using standard reagents (Microbix Biosystems, Ontario, Canada). Recombinant adenovirus was amplified on HEK293 cells. 25 Purified virus was generated from infected 293 cells by lysis in virus storage medium (10 mm Tris (pH 7.4), 1 mm MgCl 2 and 10% glycerol). The lysate was spun at 800 g and the resulting viral supernatant was free of cellular debris. Further purification was carried out on a 1.25 g/ml to 1.4 g/ml caesium chloride step gradient at 150 000 g for 2 h at 20 o C. The virus was harvested and then further purified on a second caesium chloride gradient (1.35 g/ml) at 150 000 g for 18 h at 20 o C. The purified virus was desalted by dialysis using 2000 MWCO dialysis cassettes (Slide-A-Lyzer; Pearce, IL, USA) with virus storage medium at 4 o C over 24 h with four dialysis changes. The purified virus was stored at Ϫ70 o C, with parallel aliquots for plaque titration carried out in triplicate in the standard manner. As a range of p.f.u. per injection was used, dilutions were made, and titrations of parallel aliquots performed.
Screening of adenoviral preparations to exclude wildtype contamination
Preparations of recombinant adenovirus were checked for wild-type contamination by use of the supernatant rescue assay. 26 Recombinant adenovirus was added to confluent cultures of HeLa cells at a MOI of 30. Three
Gene Therapy days later the supernatant was removed and 300 l was added per well of a 24-well plate for 6 h. The medium was replaced and the cytopathic effect was examined by direct microscopic examination 4-6 days later. This has a sensitivity for the detection of wild-type virus of 1 in 10 9 in a recombinant viral preparation. 26 In addition, no recombinant preparation produced cell death in primary rat neonatal myocytes despite high multiplicity of infection (p.f.u. у 100 per cell) with an observation periods of 10 days, whereas wild-type virus produced cell death within 3 days at a multiplicity of infection of 1.
Intracoronary gene transfer
The right common carotid artery was exposed and a 3.5 Fr haemostatic sheath (Cook, Bjaeverskov, Denmark) inserted. 1000 IU of heparin (Leo Laboratories, Buckinghamshire, UK) were administered intra-arterially before catheterisation. Rabbits were catheterised using purposemade catheters. These were based on a 3 Fr Royal Flush radio-opaque nylon catheter and were 20 cm in length, with a 70°angle to a 1-cm Macartney tip (Cook). The catheter was manipulated under fluoroscopic guidance (Xi-Scan Model 1000-1 miniature C-arm; Xi-Tech, CT, USA) to the left coronary ostium and into the main branch of the left coronary artery, analogous to the circumflex artery of man. Catheter position was confirmed by injection of radio-opaque non-ionic contrast (Omnipaque ; Nycomed, Birmingham, UK). The adenovirus in 1 ml of virus storage medium was injected over 1 min with a non-occlusive engagement. The rabbit was monitored for 5 min after vector delivery before recovery.
Arterial pressure was recorded using a MLT0698 blood pressure transducer (ADInstruments, Sussex, UK) connected to a ML117 bridge amplifier (ADInstruments) via the sidearm of the haemostatic sheath. ECG leads were connected to a pre-amplifier MLA0313 (ADInstruments) and then a ML131 Bio Amplifier (ADInstruments). Oxygen saturation was monitored using a small lingual clip sensor placed on the ear (Model 200SL, Nonin Medical Inc, Plymouth, MN, USA) using a veterinary pulse oximeter (Model 8600V; Nonin Medical Inc). Oxygen saturation was maintained above 75% using a small animal ventilator at 0.5 Hz, with a mean pressure of 2.1 cm H 2 O, and inspiratory/expiratory ratio of 1 (Zoovent, Model CWC600AO, Hillmoore Consultants, Milton Keynes, UK). The Bridge and Bio Amplifiers and the pulse oximeter were connected to a 4/S MacLab system (ADInstruments) and an Apple Macintosh Performa 6320 for on-line recording. All procedures were recorded on super-VHS tape at 625 lines (400 lines horizontal resolution) at 28 frames/s, with a video recorder (Model HR-S5900CK, JVC (UK) Ltd, London, UK) and images annotated for blind analysis.
Pre-treatment of the coronary vasculature
To alter the heart rate and vascular permeability of the coronary circulation several pre-treatments were administered. 1 mg of adenosine (Sigma, Poole, UK) was given in 1 ml of saline, between 0 and 15 min before delivery of adenovirus. In another series of experiments, adenovirus was delivered in nominally calcium-free solution. 0.9 ml of Krebs-Henseleit solution with 50 m calcium was added to either 0.1 ml of virus storage medium or 0.1 ml of recombinant adenovirus at 1 x 10 11 p.f.u./ml and delivered over 1 min occlusive engagement in the circumflex territory. Previous work showed that at a concentration of 10 -10 m topical administration of vascular endothelial growth factor (VEGF), to coronary venules significantly increased permeability to albumin, by approximately three-fold. This effect started almost immediately, reached a peak at 1-3 min and was sustained for 5-10 min. 27 We aimed to achieve a final concentration of VEGF in the coronary circulation of 10 -10 m infused over 5 min, by adding 0.76 g of recombinant VEGF (Sigma) per animal. Adenovirus was then infused 3 min later.
Occlusive coronary engagement
To perform occlusive coronary engagements and to decrease the chance of ischaemic VF, we delivered recombinant adenovirus with a perfluorocarbon emulsion. Perfluorodecalin (38.5% w/v) in Ringer's saline was stabilised with perfluorodimorphinopropane (1.5% w/v) and emulsified with lecithin (2.5% w/v). The emulsion was produced ultrasonically according to standard methods and the mean droplet size was 250 nm. 0.9 ml of perfluorodecalin was oxygenated for 5 min immediately before gene delivery. Oxygenated perfluorodecalin was mixed with either 0.1 ml of virus storage medium or 0.1 ml of recombinant adenovirus at 1 x 10 11 p.f.u./ml and was then delivered over an occlusive engagement in the circumflex territory, until there was ST elevation that was sustained for 24 ± 16 s. Perfluorodecalin did not affect gene transfer in vitro as assessed by plaque titrations of adenovirus.
High pressure gene delivery
High pressure adenoviral gene delivery was achieved using a modification to the approach of Hajjar et al. 12 The right carotid artery was cannulated as before, and a 0.014 high fidelity pressure wire (RADI Medical System, Uppsala, Sweden) was manipulated into the left ventricle. The pressure wire was connected to a RADI Medical Systems PGA10, and left ventricular pressure was recorded using the MacLab system. This allowed simultaneous measurement of both arterial and left ventricular pressure. A median sternotomy was performed using a sterile technique and care taken to avoid the pleura. The pericardium was incised and using a 23 G needle, the left ventricle was entered and the needle guided to the left ventricular outflow tract under fluoroscopic guidance. 1 x 10 10 p.f.u. of recombinant adenovirus in 3 ml of saline or nominal calcium Krebs-Henseleit buffer was injected whilst the aorta and pulmonary artery were clamped for 10 s. The animal was monitored for 5 min before closure of the chest and neck, and 100 mg of benzylpenicillin was administered i.v.
Detection of transgene expression
Rabbits were killed at day 3 or 5 by lethal injection of pentobarbitone (Sagatal, 60 mg/ml; Rhô ne Mérieux, Essex, UK) and the hearts were rapidly excised, rinsed and retrogradely perfused with 100 ml of PBS. For gene transfer experiments using vectors encoding LacZ, the hearts were fixed and stained as described by Guzman et al. 28 Hearts were perfusion-fixed with 1.25% glutaraldehyde in PBS for 15 min. The hearts were then flushed with 50 ml of PBS and perfused with X-gal stain solution (400 g/ml 5-bromo-4-chloro-3-indonyl ␤-d-galactopyranoside (X-gal), 5 mm potassium ferriferrocyanide, 1 mm MgCl 2 in PBS). The hearts were sectioned perpendicular to the long axis at 3-mm intervals and further stained in X-gal at 37°C for 2 h. The heart sections were then washed with PBS and fixed in 10% formalin before paraffin embedding and counterstaining with haemotoxylin and eosin. Sections were coded and examined for positive cells, with five sections from each heart within each group examined. The mean number of positive cells from each heart within each group was subsequently analysed using the analytical package Statview (StatView version 1.04, Abacus Concepts, Berkeley, CA, USA).
